Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 59Nivolumab 19atezolizumab 8Ipilimumab 8Docetaxel 7avelumab 6Paclitaxel 6cemiplimab 5Specimen Handling 5Cyclophosphamide 5Biopsy 5Taxes 4Pemetrexed 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Gemcitabine 4Carboplatin 4utomilumab 3epacadostat 3durvalumab 3Radiotherapy 3Cisplatin 3Cetuximab 3tremelimumab 2tislelizumab 2sargramostim 2poly ICLC 2obinutuzumab 2fludarabine 2enzalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Rosiglitazone × Dermatologic × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡